TULLIS DICKERSON CAPITAL FOCUS III L.P. 13D and 13G filings for Exagen Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-02-13 06:13 am Purchase |
2023-12-31 | 13G | Exagen Inc. XGN |
TULLIS DICKERSON CAPITAL FOCUS III L.P. | 1,867,116 10.700% |
9,167 (+0.49%) |
Filing |
| 2023-02-07 12:54 pm Sale |
2022-12-31 | 13G | Exagen Inc. XGN |
TULLIS DICKERSON CAPITAL FOCUS III L.P. | 1,857,949 11.380% |
-10,190 (-0.55%) |
Filing |
| 2022-02-14 1:10 pm Sale |
2021-12-31 | 13G | Exagen Inc. XGN |
TULLIS DICKERSON CAPITAL FOCUS III L.P. | 1,868,139 11.560% |
-22,383 (-1.18%) |
Filing |
| 2021-02-16 06:21 am Sale |
2020-12-31 | 13G | Exagen Inc. XGN |
TULLIS DICKERSON CAPITAL FOCUS III L.P. | 1,890,522 14.600% |
-243,584 (-11.41%) |
Filing |